UK-432097

• Description :

  UK-432097 is a highly potent and selective A2AAR agonist with a pKi of 8.4 for human A2AAR. UK-432097 has anti-inflammatory and anti-aggregatory properties. UK-432097 has the potential for COPD (Chronic Obstructive Pulmonary Disease) research[1][2][3].

• UNSPSC :

  12352005

• Target :

  Adenosine Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/uk-432097.html

• Purity :

  98.9

• Solubility :

  10 mM in DMSO

• Smiles :

  O[C@H]1[C@@H](O[C@H](C(NCC)=O)[C@H]1O)N2C3=NC(C(NCCNC(NC4CCN(C5=CC=CC=N5)CC4)=O)=O)=NC(NCC(C6=CC=CC=C6)C7=CC=CC=C7)=C3N=C2

• Molecular Formula :

  C40H47N11O6

• Molecular Weight :

  777.87

• References & Citations :

  [1]Fei Xu, et al. Structure of an agonist-bound human A2A adenosine receptor. Science. 2011 Apr 15;332 (6027) :322-7.|[2]Kenneth A Jacobson, et al. Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. Front Cell Neurosci. 2019 Mar 28;13:124.|[3]J Daniel Hothersall, et al. Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics. Mol Pharmacol. 2017 Jan;91 (1) :25-38.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [380221-63-6]